Defence’s Corporate Updates, Arranges Financing
Vancouver, British Columbia--(Newsfile Corp. - September 27, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Melanoma
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2...
Sensus Healthcare Sells SRT System to Providence Swedish Hospital
Continues customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancersBOCA RATON, Fla., Sept. 25, 2024...
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumorsLEXINGTON, Mass., Sept. 24,...
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept....
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in...
Achilles Therapeutics Announces Strategic Update
–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities...
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company...
New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma
Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society 2024...
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
MyRisk®, FirstGene®, Prequel®, and Foresight® studies among 10 datasets to be shared by MyriadSALT LAKE CITY, Sept. 18, 2024 (GLOBE...
14th Annual Nikon Small World in Motion Competition Winner Captures Embryonic Development in Fruit Flies
Detailing the intricate process of early embryogenesis, this year's winning video provides insights into fundamental biological processes with far-reaching implications....
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
PHOENIX & FRIENDSWOOD, Texas--(BUSINESS WIRE)--$CSTL #COO--The Arizona Bioindustry Association, Inc. (AZBio) and Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving...
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
PHOENIX & FRIENDSWOOD, Texas--(BUSINESS WIRE)--$CSTL #COO--The Arizona Bioindustry Association, Inc. (AZBio) and Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving...
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are...
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically...
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the...
Cantargia Presents Positive Results at ESMO Congress 2024 Showing Benefit of Nadunolimab Combination Therapy in Cancer After Relapse on PD1-inhibitors
LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today presented data from...
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a...
Moderna R&D Day Highlights Progress and Strategic Priorities
Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination...
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
Elraglusib is a Class-Leading GSK-3β Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer TrialsOrphan Drug Designation...